Skip to main content
Top
Published in: BMC Public Health 1/2015

Open Access 01-12-2015 | Research article

Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study

Authors: Naohiko Masaki, Yoko Yamagiwa, Takuro Shimbo, Kazumoto Murata, Masaaki Korenaga, Tatsuya Kanto, Masashi Mizokami, and the prefectural members contributing to the Japanese Interferon Database

Published in: BMC Public Health | Issue 1/2015

Login to get access

Abstract

Background

Many patients with chronic hepatitis C have been treated with interferon (IFN) therapy in Japan, especially after the introduction of subsidies for medical expenses in 2008. However, its performance and outcome have never been evaluated. Therefore, a nationwide, mail-based, retrospective cohort study was conducted.

Methods

Regional disparities in the demographic features, treatment performance, and virological response were evaluated using an intent-to-treat design. The participating prefectures were classified into nine regions from north to south (Hokkaido/Tohoku, Kanto, Shin-etsu, Hokuriku, Tokai, Kinki, Chugoku, Shikoku, and Kyushu). Multivariate logistic regression analysis was performed to select predictive factors for treatment performance and outcome.

Results

From December 2009 to May 2013, 16,854 patients with chronic hepatitis C were registered from 37 prefectures in Japan (median age: 60 years; 50.4 % male; 74.8 % IFN-naïve; HCV genotype [1 or 2]/viral load [high (≥5 log IU/mL) or low (<5 log IU/mL)]: 1/high = 58.2 %, 1/low = 5.2 %, 2/high = 27.3 %, 2/low = 7.5 %; 83.4 % treated with peginterferon-α and ribavirin). Mean age, proportion of elderly patients (≥65 years), male sex, IFN-experienced, and HCV genotype were significantly different among the nine regions (all P < 0.001). Regional disparities were independently selected as one of the predictive factors for treatment performance and outcome in patients treated with peginterferon-α and ribavirin, which revealed two regions that required further investigation.

Conclusions

Regional disparities still exist in IFN therapy, and are strongly associated with treatment performance and outcome. Since the accessibility to medical resources for individual patients seemed to be different among the nine regions, public health actions should be focused on how to construct and properly manage consultation networks between base hospitals and local clinics, especially in those regions with low population density.
Appendix
Available only for authorised users
Literature
2.
go back to reference Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–43.CrossRefPubMedPubMedCentral Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–43.CrossRefPubMedPubMedCentral
3.
go back to reference Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.CrossRefPubMedPubMedCentral Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.CrossRefPubMedPubMedCentral
4.
go back to reference Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.CrossRefPubMedPubMedCentral Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.CrossRefPubMedPubMedCentral
5.
go back to reference Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.CrossRefPubMed Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.CrossRefPubMed
6.
go back to reference McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.CrossRefPubMed McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.CrossRefPubMed
7.
go back to reference Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219–27.CrossRefPubMed Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219–27.CrossRefPubMed
8.
go back to reference Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403–13.CrossRefPubMed Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403–13.CrossRefPubMed
9.
go back to reference Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.CrossRefPubMed Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.CrossRefPubMed
10.
go back to reference Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–23.CrossRefPubMed Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–23.CrossRefPubMed
11.
go back to reference Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.CrossRefPubMedPubMedCentral Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.CrossRefPubMedPubMedCentral
13.
go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.CrossRefPubMed
14.
go back to reference Izumi N, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347–68.CrossRef Izumi N, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347–68.CrossRef
15.
go back to reference Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefPubMed Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefPubMed
16.
go back to reference Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V, et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012;56:2398–403.CrossRefPubMed Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V, et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012;56:2398–403.CrossRefPubMed
17.
go back to reference McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy. 2013;11:53–63.CrossRefPubMed McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy. 2013;11:53–63.CrossRefPubMed
18.
go back to reference O’Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, et al. Geographic variation in the treatment of acute myocardial infarction: the cooperative cardiovascular project. JAMA. 1999;281:627–33.CrossRefPubMed O’Connor GT, Quinton HB, Traven ND, Ramunno LD, Dodds TA, Marciniak TA, et al. Geographic variation in the treatment of acute myocardial infarction: the cooperative cardiovascular project. JAMA. 1999;281:627–33.CrossRefPubMed
19.
go back to reference Gentry SE, Massie AB, Cheek SW, Lentine KL, Chow EH, Wickliffe CE, et al. Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant. 2013;13:2052–8.CrossRefPubMedPubMedCentral Gentry SE, Massie AB, Cheek SW, Lentine KL, Chow EH, Wickliffe CE, et al. Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant. 2013;13:2052–8.CrossRefPubMedPubMedCentral
20.
go back to reference Brantley-Sieders DM, Fan K-H, Deming-Halverson SL, Shyr Y, Cook RS, Local breast cancer spatial patterning. A tool for community health resource allocation to address local disparities in breast cancer mortality. PLoS One. 2012;7, e45238.CrossRefPubMedPubMedCentral Brantley-Sieders DM, Fan K-H, Deming-Halverson SL, Shyr Y, Cook RS, Local breast cancer spatial patterning. A tool for community health resource allocation to address local disparities in breast cancer mortality. PLoS One. 2012;7, e45238.CrossRefPubMedPubMedCentral
21.
go back to reference Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, et al. Analysis of site performance in academic-based and community-based centers in the IDEAL Study. J Clin Gastroenterol. 2013;47:e91–5.CrossRefPubMed Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, et al. Analysis of site performance in academic-based and community-based centers in the IDEAL Study. J Clin Gastroenterol. 2013;47:e91–5.CrossRefPubMed
22.
go back to reference Thomas DL. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence. Top Antivir Med. 2014;21:152–6.PubMed Thomas DL. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence. Top Antivir Med. 2014;21:152–6.PubMed
Metadata
Title
Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study
Authors
Naohiko Masaki
Yoko Yamagiwa
Takuro Shimbo
Kazumoto Murata
Masaaki Korenaga
Tatsuya Kanto
Masashi Mizokami
and the prefectural members contributing to the Japanese Interferon Database
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2015
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-015-1891-2

Other articles of this Issue 1/2015

BMC Public Health 1/2015 Go to the issue